FRIDAY 8 OCTOBER 2021
09:00
ECMM council meeting
12:00
Coffee break
Plenary Session 1 The 10th TIMM Anniversary
Chairs: Neil Gow, United Kingdom, FECMM & Martin Hoenigl, Austria, FECMM
12:30
PS 1.1 The life and death of diagnostic methods in mycology
Sybren de Hoog, the Netherlands, FECCM
12:50
PS 1.2 Highlights of clinical trials in medical mycology
George Petrikkos, Greece
13:10
PS 1.3 Celebration of Fungal Facts and Science
Adilia Warris, United Kingdom, FECMM
13:45
Parallel Symposia 1-4
Symposium 1 Diagnostics Endemic Mycoses
Chairs: Thuy Le, USA & Tadeja Matos, Slovenia
13:45
S01.1 Coccidioidomycosis: Diagnostics
Derek Bays, USA
14:05
S01.2 Novel Non-Culture Diagnostics for Talaromycosis
Thuy Le, USA
14:25
S01.3 Histoplasmosis
Alessandro Pasqualotto, Brazil, FECMM
14:45
S01.4 Molecular diagnosis of sporotrichosis from patients with subcutaneous lesions of Antioquia (Colombia) 1976 - 2021
Erika Sánchez Cifuentes, Colombia
15:00
S01.5 Ex-vivo and in-vivo production of ROS and cytokine profile of LASER-irradiated murine neutrophiles in infection by Paracoccidioides brasiliensis
Bruno José Nascimento Gomes, Brazil
Symposium 2 Engaging the public - medical mycology advocacy, policy and the general public
Chairs: Donna MacCallum, United Kingdom & Esther Segal, Israel, FECMM
13:45
S02.1 Strategies to change public perceptions of fungal disease
Lorna Barnes, United Kindom
14:05
S02.2 advocacy, policy
David Denning, United Kingdom, FECCM
14:25
S02.3 engaging public and politics in Low Middle Income Countries
Bright Ocansey, Ghana
14:45
S02.4 Onsite trainings to improve outcomes of People Living with HIV (PLHIV) in Sub-Saharan African countries
Aude Sturny-leclere, France
15:00
S02.5 Mucormycosis in Covid19 pandemic: Another foe joining hands with SARS-CoV-2 in India.
Jagdish Chander, India
Symposium 3 Clinical Risk and prevention of IFI in patients receiving biologics and targeted therapies
Chair: Jose Aguado, Spain, FECMM
13:45
S03.1 IFI in patients receiving biologics and targeted therapies: Which drugs and clinical situations really increases the risk?
Jose Aguado, Spain, FECMM
14:05
S03.2 Is antifungal prophylaxis necessary?
Malgorzata Mikulska, Italy, FECMM
14:25
S03.3 Biologic and targeted therapies for the treatment of IFI
Elham Khatamzas, Germany
14:45
S03.4 Immune dysregulation in psoriasis patients with skin or mucosal candidiasis during IL-17 or IL-(12)/23 inhibitor therapy
Mariolina Bruno, the Netherlands
Sponsored symposium 4 Update on new antifungals
More information on https://www.timm2021.org/sponsored-symposia/
15:15
Coffee break
15:30
Sponsored Diagnostic Symposium 1
More information on https://www.timm2021.org/sponsored-symposia/
16:30
Time to switch rooms
16:45
Sponsored Integrated Symposium 1
More information on https://www.timm2021.org/sponsored-symposia/
18:15
Welcome address
18:30
E. Drouhet lecture (ECMM)
The history of the ECMM and TIMM – Jacques F. Meis, the Netherlands, FECCM
19:00
Global warming and fungal disease
Arturo Casadevall, USA
19:30
Welcome reception